SELLAS Life Sciences Group enters September with one of the most charged short-selling setups in small-cap biotech — 41% of the free float sold short, essentially no shares left to borrow, and a stock that has surged 32% in a month while slipping 6% this week.
The borrow market tells the most extreme story here. Availability has collapsed to just 0.17% of short interest — meaning for every 600 shares already lent out, fewer than one remains available to borrow. That is functionally a closed lending pool, and the squeeze potential is real. The move was abrupt: three weeks ago availability was running near 10–17%, then dropped sharply through the week of August 24 and has barely recovered since. Cost to borrow has eased from a peak of around 19% in late July to roughly 12% now, which looks like a modest relief — but at 12% annually, lenders are still extracting a meaningful carry cost from short holders. Short interest itself has crept higher all month, reaching 40.6% of the free float and adding about 5.8% in the past week alone. Days to cover from FINRA's fortnightly data stands at 10.4 — over two trading weeks of average volume needed to unwind current positions. The ORTEX short score, running at 82.9 out of 100 and ranked in the bottom 2nd percentile of the universe on short positioning, captures how extreme this setup is.
Options traders are not signalling panic in either direction. The put/call ratio is 0.48, sitting almost exactly on its 20-day average with a z-score near zero — close to the 52-week high of 0.51 but far from a distressed reading. That near-neutral stance from options desks is a contrast to the intensity of the short book. If anything, it suggests the options market is not layering on additional downside bets on top of the already-heavy short position. The setup reads as a stock under sustained short pressure rather than one where hedgers are scrambling for protection.
The Street view offers bulls some headline comfort, but the analyst picture carries important caveats. The most recent target change on record — Maxim Group raising to $10 in March 2026 — is six months old and well below the current price of $13.22. The mean price target of $32.50 implies substantial return potential from here, but those figures appear stale relative to the stock's move this year (up roughly 254% year-to-date by some measures) and should be treated carefully. The company carries deeply negative return metrics typical of a clinical-stage operation, with an F-score of 2 and negative ROA, and the EPS surprise factor score of 69 is the brightest fundamental signal on the board. Momentum is the dominant driver of the investment case, not fundamentals.
Institutional flow adds a notable layer. BlackRock has been building, filing a 13G/A in April showing a 6.8% stake, up from 5.4% previously. State Street crossed the 5% threshold in August and filed its own 13G. Meanwhile, Anson Funds trimmed from 5.7% to 4.9% as of February. These are passive positions — no 13D activist is on the register — but the index-fund accumulation at above-5% levels is structurally meaningful. As with all 13D/G disclosures, stakes reflect positions at the time of filing and holders can exit below 5% without further disclosure.
Recent earnings reactions add context for what an upcoming catalyst could mean. The last four quarterly prints produced average next-day gains of around 6.6–11.9% and five-day moves of 14–25%. The next earnings event is pencilled in for November 12. Between now and then, any clinical trial readout or FDA-related update is the catalyst the market will watch most closely — particularly given that the borrow pool is essentially shut and short holders face meaningful costs to stay in position.
See the live data behind this article on ORTEX.
Open SLS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
